CLEAR LABELS Act: New Drug Supply Chain Country-of-Origin Labeling Requirements for Distributors

Senator Tim Scott (R-SC) introduced the CLEAR LABELS Act (S. 5505) on December 11, 2024, requiring country-of-origin labeling on prescription drug packaging. If enacted, wholesale drug distributors would face new compliance obligations to ensure medication labels disclose where active pharmaceutical ingredients (APIs) are manufactured and where finished drugs are packaged—adding a labeling verification step to existing DSCSA supply chain security protocols.

Regulatory Context

The CLEAR LABELS Act (Country Labeling Enabling and Allowing Recognizable Labels Encouraging Secure and Safe Supply Chains) addresses a gap in current pharmaceutical labeling regulations. Under 21 CFR Part 201, FDA-mandated prescription drug labels must include the name and place of business of the manufacturer, packer, or distributor—but these designations often reflect the U.S.-based label holder rather than the actual manufacturing location. The National Defense Authorization Act for Fiscal Year 2020 (Section 3613) required country-of-origin labeling for DoD pharmaceutical purchases, but no equivalent requirement exists for commercial distribution channels.

The proposed legislation would amend the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) to require all prescription drug labels to display:

1. Country of API manufacture
2. Country of finished drug product manufacturing
3. Country of packaging and labeling operations

This mandate applies to drugs entering interstate commerce—the same jurisdictional scope as DSCSA transaction requirements under 21 U.S.C. 360eee-1.

Key Requirements

Under the CLEAR LABELS Act, manufacturers and repackagers must include country-of-origin information on the immediate container label and outer packaging. The bill does not specify label format or size requirements—FDA would promulgate those details through rulemaking within 180 days of enactment.

The bill includes a three-year implementation timeline from enactment, allowing manufacturers to exhaust existing label inventory before the requirement takes effect. Drugs already in distribution at the effective date would be grandfathered—no relabeling of existing stock required.

For wholesale drug distributors, the compliance question is not "must I create these labels?" (that falls to manufacturers) but "must I verify these labels are present before distribution?" The bill text does not explicitly impose verification duties on distributors, but FDA's enforcement posture under 21 CFR Part 205 (Guidelines for State Licensing of Wholesale Prescription Drug Distributors) has historically held distributors accountable for receiving properly labeled product.

Impact on Wholesale Drug Distributor Operations

If the CLEAR LABELS Act passes, wholesale drug distributors would need to integrate country-of-origin label verification into receiving workflows. Current distributor compliance programs under DSCSA focus on transaction documentation (TI/TS/TP) and product identifier verification. Adding a label content check introduces a new inspection point at intake.

Distributors handling repackaged or relabeled drugs face higher exposure. Third-party logistics providers that offer repackaging services would need to source compliant label stock and maintain records of which country-of-origin information applies to each lot—similar to current lot traceability under 21 CFR Part 205.50(g).

State boards of pharmacy may incorporate country-of-origin labeling into license renewal inspections. Ohio and Texas—the two states with the highest number of licensed distributors in ColdChainCheck's directory (412 and 287 entities respectively)—both conduct routine inspections under their Prescription Drug Wholesale Distributor License programs. If FDA issues guidance that country-of-origin label compliance is a prerequisite for interstate distribution, state boards will likely add it to their inspection checklists.

For distributors importing finished drugs under FDA Import Alert procedures or through authorized importers under Section 801(d)(1) of the FD&C Act, country-of-origin labeling creates additional documentation requirements. Distributors already maintain country-of-origin certificates for customs clearance; the CLEAR LABELS Act would require that information to flow through to the consumer-facing label—closing the loop between import records and point-of-dispense packaging.

The bill does not create new penalties specific to country-of-origin labeling violations. Misbranded drug provisions under 21 U.S.C. 352 would apply, meaning distributors knowingly handling improperly labeled product could face warning letters, import refusals, or state license suspension—the same enforcement tools FDA and state boards currently use for other labeling violations.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors and 3PLs tracked in ColdChainCheck's directory, 1,234 hold active FDA establishment registrations—meaning 96.8% of entities are already subject to FDA labeling enforcement under 21 CFR Part 201. If the CLEAR LABELS Act passes, these entities would need to verify country-of-origin information on products they handle, adding a new dimension to existing receiving inspection protocols.

The current compliance score distribution suggests varied preparedness for additional labeling requirements. The 28 entities with Excellent scores (85-100 points) typically maintain NABP accreditation and multi-state licensure—indicating established quality systems that could absorb new label verification steps more readily. The 919 entities in the Fair tier (35-64 points) represent the bulk of the industry: smaller regional distributors with fewer documented compliance signals. For these entities, country-of-origin label verification would require updating SOPs, training receiving staff, and potentially implementing new inspection checklists—operational lift that may strain lean QA teams.

Entities with FDA recalls on record (73 in ColdChainCheck's directory) face higher scrutiny. If FDA links a future recall to country-of-origin labeling non-compliance, distributors with existing enforcement history may see faster escalation to warning letters or consent decrees. State boards reviewing license renewals often weigh prior violations when assessing corrective action plans.

Practical Guidance for Compliance Officers

• Audit current receiving SOPs: Review whether intake inspection forms include a "label content verification" step. If country-of-origin labeling becomes mandatory, this check must cover API sourcing, manufacturing location, and packaging site—not just NDC and lot number.

• Identify repackaging risk: Distributors that repackage, relabel, or co-pack products face direct labeling obligations. Use ColdChainCheck's directory to cross-reference trading partners' FDA registration status and recall history before accepting repackaged products. Entities with poor compliance scores may have weaker label control processes.

• Monitor state board guidance: Ohio (412 tracked entities) and Texas (287 tracked entities) lead in distributor density. If either state board issues advisory opinions on country-of-origin labeling expectations, that guidance often shapes nationwide practice. ColdChainCheck tracks state-level enforcement actions in entity profiles.

• Document import chain-of-custody: For distributors handling imported products, maintain records linking customs entry documents (which include country-of-origin data) to specific lots in inventory. This documentation supports label verification and provides an audit trail if FDA questions country-of-origin accuracy.

ColdChainCheck does not currently score country-of-origin labeling compliance (the requirement does not yet exist). If the CLEAR LABELS Act passes and FDA issues enforcement guidance, we will evaluate adding it as a scoring dimension. Related regulatory updates are tracked in our wholesale distributor compliance guide.

Disclaimer: This article is informational only and does not constitute legal or regulatory advice. Wholesale drug distributors should consult legal counsel and verify all requirements with the FDA and relevant state boards of pharmacy before implementing compliance procedures.